For the first time, a laboratory-made, 3D-printed cornea has been successfully implanted in a human, allowing him to recover his sight. It is not a futuristic announcement nor a distant promise: the operation has already taken place and marks a concrete transition towards a more accessible medicine, capable of overcoming one of the greatest limitations of transplants, namely the lack of available tissues.
The operation was performed on October 29, 2025 on a patient considered legally blind. The cornea was developed by Precise Bio, an American company specializing in bio-manufacturing, which defined the result as a world first. And it’s hard to blame her. Because here we are not talking about just any artificial cornea, but about a tissue created from human ocular cells grown in the laboratory, without the direct use of a donor.
The problem, which has been known for some time, is enormous: in the world there is a dramatic disproportion between those who need a cornea transplant and those who can receive one. Today, on average, a single donated cornea is available for around 70 people who need it to see again. Very long waiting lists, surgeries postponed for years, lives put on hold. The technology developed by Precise Bio could radically change this scenario, because from a single donated cornea it would be possible to obtain hundreds of grafts grown in the laboratory.
The transplant was performed by Dr. Michael Mimouni, director of the cornea unit at the Rambam Medical Center in Israel. After the surgery he spoke of a difficult moment to forget: seeing a cornea created in the laboratory, from live cells, giving back sight to a person. Not a symbolic result, but a real, measurable, human change.
PB-001
The graft is called PB-001 and was designed to reproduce the same characteristics of a natural cornea: transparency, resistance, flexibility. Before reaching humans it had been tested on animal models, demonstrating that it could integrate with the tissues of the eye without rejection. A fundamental step, because the cornea is not just a “lens”, but a living structure that must communicate with the organism.
The cornea is the outer layer of the eye that protects the iris and pupil. It can become cloudy due to infection, trauma, scarring or degenerative disease, severely affecting vision. It is one of the most common causes of reversible blindness, at least in theory. In practice, however, without an available fabric, reversibility remains only on paper.
PB-001 is currently at the center of a phase 1 clinical trial in Israel, which will involve between 10 and 15 patients with serious corneal problems related to fluid accumulation. The objective is to evaluate the safety and effectiveness of the graft over time. The first complete results are expected in the second half of 2026, with a follow-up six months after surgery.
Another interesting aspect concerns practicality. These corneas can be preserved for a long time through cryopreservation, shipped and used with the same surgical techniques already in use. They arrive already mounted on standard devices and, during implantation, they open taking on the natural shape of the cornea. A detail that is anything but secondary, because it reduces the time and complexity of the intervention.
According to Anthony Atala, doctor and co-founder of Precise Bio, the possibility of producing “ready-to-use” tissues on demand could change the way we understand transplants. No longer a race against time and the availability of donors, but a programmable, fairer, more sustainable medicine.
It is not the solution to all problems, and it is not yet a technology for everyone. But it is a solid, verifiable start that speaks of regeneration rather than scarcity, of access rather than waiting. And above all it demonstrates that, when research works, rhetoric is not needed: just look at a person who can see again.
You might also be interested in:
